Vincerx Pharma (NASDAQ:VINC) & Revelation Biosciences (NASDAQ:REVB) Head-To-Head Survey

Vincerx Pharma (NASDAQ:VINC) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Vincerx Pharma and Revelation Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vincerx Pharma	0	0	1	0	3.00
Revelation Biosciences	0	0	0	0	N/A

Vincerx Pharma currently has a consensus price target of $5.00, suggesting a potential upside of 474.71%. Given Vincerx Pharma’s higher probable upside, analysts clearly believe Vincerx Pharma is more favorable than Revelation Biosciences.

Volatility and Risk

Vincerx Pharma has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Insider and Institutional Ownership

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 20.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 1.4% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Vincerx Pharma and Revelation Biosciences’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16 million	($1.89)	-0.46
Revelation Biosciences	N/A	N/A	-$120,000.00	$30.41	0.06

Vincerx Pharma is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vincerx Pharma and Revelation Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-187.73%	-126.26%
Revelation Biosciences	N/A	-84.25%	-51.31%

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

About Revelation Biosciences

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.